سعر ماكروفيوران 50مجم 30 كبسولة 2025

Macrofuran 50 mg (Egypt; Kahira): oral capsules of the nitrofuran urinary antibacterial nitrofurantoin 50 mg, pack of 30 capsules.

• Urinary tract infections due to susceptible strains of E. coli, enterococci, S. aureus and certain Klebsiella and Enterobacter species; not indicated for pyelonephritis or perinephric abscesses.Population: Adults and children over 1 monthDailyMed (U.S. National Library of Medicine)

• Nausea, emesis and anorexia occur most often; abdominal pain and diarrhoea are less common; these are dose-related.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity reactions (angioedema, rashes, pruritus, urticaria, anaphylaxis, arthralgia, drug fever, lupus-like syndrome) are the most frequent spontaneously reported events.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Neurological effects including peripheral neuropathy, asthenia, vertigo, dizziness, headache and drowsiness; benign intracranial hypertension rarely. Transient alopecia, exfoliative dermatitis and erythema multiforme rarely.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Anuria, oliguria or significant renal impairment (CrCl under 60 mL/min).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Pregnant patients at term (38 to 42 weeks), during labour and delivery or when labour is imminent, and neonates under one month (risk of haemolytic anaemia).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Previous cholestatic jaundice or hepatic dysfunction associated with nitrofurantoin, and known hypersensitivity to nitrofurantoin.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Acute, subacute or chronic pulmonary reactions (including interstitial pneumonitis and pulmonary fibrosis, mainly with therapy of six months or longer) have occurred, sometimes fatal; stop the drug if they occur.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hepatic reactions including hepatitis, cholestatic jaundice, chronic active hepatitis and hepatic necrosis occur rarely; fatalities reported; withdraw immediately if hepatitis occurs.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Peripheral neuropathy, which may be severe or irreversible, has occurred; renal impairment, anaemia, diabetes, electrolyte imbalance, vitamin B deficiency and debilitating disease increase the risk. Optic neuritis has been reported rarely.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Magnesium trisilicate antacidsAntacids containing magnesium trisilicate reduce the rate and extent of nitrofurantoin absorption.DailyMed (U.S. National Library of Medicine)
• Uricosuric drugs (probenecid, sulfinpyrazone)Can inhibit renal tubular secretion of nitrofurantoin, raising serum levels (toxicity) and lowering urinary levels (reduced efficacy).DailyMed (U.S. National Library of Medicine)
• Urine glucose tests (Benedict's and Fehling's solutions)Nitrofurantoin may cause a false-positive urine glucose reaction with Benedict's or Fehling's solutions (not with enzymatic tests).DailyMed (U.S. National Library of Medicine)

• Animal reproduction studies at up to six times the human dose showed no fetal harm, but there are no adequate controlled studies in pregnant women; use in pregnancy only if clearly needed.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Detected in human milk in trace amounts; because of possible serious reactions in nursing infants under one month, decide whether to stop nursing or the drug.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.